Illinois Municipal Retirement Fund Makes New Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Illinois Municipal Retirement Fund purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 127,160 shares of the biotechnology company’s stock, valued at approximately $2,181,000.

A number of other hedge funds also recently bought and sold shares of ADMA. Creative Planning boosted its position in ADMA Biologics by 52.0% during the third quarter. Creative Planning now owns 54,947 shares of the biotechnology company’s stock worth $1,098,000 after purchasing an additional 18,800 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of ADMA Biologics by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 1,509 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of ADMA Biologics during the third quarter valued at approximately $2,658,000. New York State Teachers Retirement System acquired a new position in shares of ADMA Biologics during the third quarter valued at approximately $1,821,000. Finally, SteelPeak Wealth LLC acquired a new position in shares of ADMA Biologics during the third quarter valued at approximately $471,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $16.39 on Friday. ADMA Biologics, Inc. has a one year low of $5.08 and a one year high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market cap of $3.87 billion, a PE ratio of 58.54 and a beta of 0.75. The stock has a 50 day moving average price of $16.75 and a 200 day moving average price of $17.98.

Analyst Ratings Changes

ADMA has been the subject of a number of research analyst reports. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright increased their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.